Страна: Канада
Език: английски
Източник: Health Canada
APIXABAN
NORA PHARMA INC
B01AF02
APIXABAN
5MG
TABLET
APIXABAN 5MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0153051002; AHFS:
APPROVED
2022-10-04
PRODUCT MONOGRAPH PR NRA-APIXABAN Apixaban Tablets 2.5 mg and 5 mg Anticoagulant Nora Pharma Inc. 1565 boul. Lionel-Boulet Varennes, QC, J3X 1P7 Canada Date of Initial Approval: MAR 21, 2022 Date of Revision: OCT 4, 2022 Submission Control No: 268199 _Pr_ _NRA-APIXABAN Product Monograph Page 2 of 77 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 10 DRUG INTERACTIONS ......................................................................................................... 19 DOSAGE AND ADMINISTRATION ..................................................................................... 24 OVERDOSAGE ....................................................................................................................... 31 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 32 STORAGE AND STABILITY ................................................................................................. 37 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 37 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 37 PART II: SCIENTIFIC INFORMATION .................................................................................... 38 PHARMACEUTICAL INFORMATION .................................................................. Прочетете целия документ